CML-623 XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib With Potential Implications for Its Clinical Use
| Autor: | Lennernäs, Hans, Liljebris, Charlotta, Brisander, Magnus, Jesson, Gerald, Andersson, Per |
|---|---|
| Zdroj: | In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S378-S379 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect